43 related articles for article (PubMed ID: 10552942)
1. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1999 Nov; 94(10):3334-9. PubMed ID: 10552942
[TBL] [Abstract][Full Text] [Related]
2. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience.
Viviani S; Notti P; Bonfante V; Verderio P; Valagussa P; Bonadonna G
Med Oncol; 2000 Feb; 17(1):59-63. PubMed ID: 10713662
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of basic fibroblast growth factor as a prognostic biomarker for the response of lung adenocarcinoma patients to bevacizumab treatment.
Jiang H; Li C; Gong Q; Qie H
Immunobiology; 2023 Nov; 228(6):152764. PubMed ID: 38043261
[TBL] [Abstract][Full Text] [Related]
4. Retracted: Analysis of the Correlation of Basic Fibroblast Growth Factor in Serum of Patients with Diffuse Large B-Cell Lymphoma with Clinicopathological Efficacy and International Prognostic Index.
Imaging CMM
Contrast Media Mol Imaging; 2023; 2023():9828072. PubMed ID: 37810489
[TBL] [Abstract][Full Text] [Related]
5. Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.
Vermeulen R; Saberi Hosnijeh F; Bodinier B; Portengen L; Liquet B; Garrido-Manriquez J; Lokhorst H; Bergdahl IA; Kyrtopoulos SA; Johansson AS; Georgiadis P; Melin B; Palli D; Krogh V; Panico S; Sacerdote C; Tumino R; Vineis P; Castagné R; Chadeau-Hyam M; ; Botsivali M; Chatziioannou A; Valavanis I; Kleinjans JCS; de Kok TMCM; Keun HC; Athersuch TJ; Kelly R; Lenner P; Hallmans G; Stephanou EG; Myridakis A; Kogevinas M; Fazzo L; De Santis M; Comba P; Bendinelli B; Kiviranta H; Rantakokko P; Airaksinen R; Ruokojarvi P; Gilthorpe M; Fleming S; Fleming T; Tu YK; Lundh T; Chien KL; Chen WJ; Lee WC; Kate Hsiao C; Kuo PH; Hung H; Liao SF
Int J Cancer; 2018 Sep; 143(6):1335-1347. PubMed ID: 29667176
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.
Akl MR; Nagpal P; Ayoub NM; Tai B; Prabhu SA; Capac CM; Gliksman M; Goy A; Suh KS
Oncotarget; 2016 Jul; 7(28):44735-44762. PubMed ID: 27007053
[TBL] [Abstract][Full Text] [Related]
7. Nuclear translocation of fibroblast growth factor-2 (FGF2) is regulated by Karyopherin-β2 and Ran GTPase in human glioblastoma cells.
Wang F; Yang L; Shi L; Li Q; Zhang G; Wu J; Zheng J; Jiao B
Oncotarget; 2015 Aug; 6(25):21468-78. PubMed ID: 26056081
[TBL] [Abstract][Full Text] [Related]
8. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.
Liekens S; Noppen S; Gijsbers S; Sienaert R; Ronca R; Tobia C; Presta M
Oncotarget; 2015 Mar; 6(7):4633-48. PubMed ID: 25609197
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.
Gharbaran R; Goy A; Tanaka T; Park J; Kim C; Hasan N; Vemulapalli S; Sarojini S; Tuluc M; Nalley K; Bhattacharyya P; Pecora A; Suh KS
J Hematol Oncol; 2013 Aug; 6():62. PubMed ID: 23988031
[TBL] [Abstract][Full Text] [Related]
10. S6K2: The Neglected S6 Kinase Family Member.
Pardo OE; Seckl MJ
Front Oncol; 2013; 3():191. PubMed ID: 23898460
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Stopeck AT; Unger JM; Rimsza LM; LeBlanc M; Farnsworth B; Iannone M; Glenn MJ; Fisher RI; Miller TP
Blood; 2012 Aug; 120(6):1210-7. PubMed ID: 22734071
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.
Rujirojindakul P; Lekhakula A
ScientificWorldJournal; 2012; 2012():215231. PubMed ID: 22629121
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of janus kinases and signal transducers and activators of transcription in cancer.
Costa-Pereira AP; Bonito NA; Seckl MJ
Am J Cancer Res; 2011; 1(6):806-16. PubMed ID: 22016828
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers.
Tamburro D; Fredolini C; Espina V; Douglas TA; Ranganathan A; Ilag L; Zhou W; Russo P; Espina BH; Muto G; Petricoin EF; Liotta LA; Luchini A
J Am Chem Soc; 2011 Nov; 133(47):19178-88. PubMed ID: 21999289
[TBL] [Abstract][Full Text] [Related]
15. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP
PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473
[TBL] [Abstract][Full Text] [Related]
16. [Role of tyrosine kinases in tumor progression of the head and neck].
Bergmann C; Wimmer E
HNO; 2009 Feb; 57(2):123-32. PubMed ID: 19194682
[TBL] [Abstract][Full Text] [Related]
17. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Kitagawa J; Hara T; Tsurumi H; Goto N; Kanemura N; Yoshikawa T; Kasahara S; Yamada T; Sawada M; Takahashi T; Shimizu M; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2009 Jan; 135(1):53-9. PubMed ID: 18592269
[TBL] [Abstract][Full Text] [Related]
18. Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations.
Anttonen A; Leppä S; Heikkilä P; Grenman R; Joensuu H
J Cancer Res Clin Oncol; 2006 Jul; 132(7):451-7. PubMed ID: 16557382
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Keller G; Schally AV; Groot K; Toller GL; Havt A; Köster F; Armatis P; Halmos G; Zarandi M; Varga JL; Engel JB
Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10628-33. PubMed ID: 16027368
[TBL] [Abstract][Full Text] [Related]
20. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
